2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5519 Molecular burden beyond MMR at 12 months defines distinct response trajectories in chronic myeloid leukemia

Rikki Williams, MD, Kendall Diebold, CNP, MSN2, Joshua Knapp, BS3, Aditi Sharma, MD4, Razan Mohty, MD5, Manuel Ricardo Espinoza-Gutarra, MD6, Sravanti Rangaraju, MD7, Kimo Bachiashvili, MD8, Pankit Vachhani, MD9, Ravi Bhatia, MD10, Jorge Cortes, MD11, Omer Jamy, MD12
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Alabama at Birmingham, Birmingham, Alabama, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 University of Alabama at Birmingham, Birmingham, Alabama, United States
6 University of Alabama at Birmingham, Birmingham, Alabama, United States
7 University of Alabama at Birmingham, Birmingham, Alabama, United States
8 University of Alabama at Birmingham, Birmingham, Alabama, United States
9 University of Alabama at Birmingham, Birmingham, Alabama, United States
10 University of Alabama at Birmingham, Birmingham, Alabama, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 University of Alabama at Birmingham, Birmingham, Alabama, United States

Background: Patients with chronic myeloid leukemia (CML) not in major molecular response (MMR; BCR::ABL1 ≤0.1%) at 12 months have heterogeneous residual disease and subsequent outcomes. We evaluated subsequent MMR and deep molecular response according to 12-month molecular burden and explored associations with post-12-month management and pre-12-month relative dose prescribed of tyrosine kinase inhibitor (TKI) in a real-world cohort of CML patients.

Methods: We retrospectively reviewed 209 patients with CML referred to a single academic center. The landmark cohort included 120 eligible patients with chronic-phase CML, documented frontline TKI therapy, and evaluable quantitative 12-month BCR::ABL1 PCR. Categories were ≤0.1%, >0.1-1%, >1-10%, and >10%. The primary outcome among patients not in MMR was first post-12-month MMR by Month 24. Secondary outcomes included any subsequent MMR, MMR at last observation, time to MMR, and cumulative achievement of MR4 and MR4.5 through Month 60. Categorical outcomes were compared using exact tests, time-to-event outcomes using Kaplan-Meier and log-rank methods, and MMR by Month 24 using univariable logistic regression with BCR::ABL1 modeled on the log10 scale. Post-12-month management was classified as TKI continuation, dose escalation, or switching. Mean relative prescribed dose was averaged across Months 3, 6, and 9; adjusted analyses included 3-month BCR::ABL1 and TKI.

Results: Median age was 56 years; 55% were female, 68% White, and 22% Black. Frontline TKIs were dasatinib (42%), imatinib (33%), nilotinib (22%), and bosutinib (3%). Median follow-up from diagnosis was 7.2 years (interquartile range [IQR], 4.7-11.7). At Month 12, 63/120 patients (52.5%) achieved MMR; 29 (24.2%) had BCR::ABL1 >0.1-1%, 12 (10.0%) >1-10%, and 16 (13.3%) >10%. Among 55/57 patients without MMR evaluable through Month 24, MMR occurred in 20/28 (71.4%), 3/12 (25.0%), and 1/15 (6.7%), respectively (p<0.001). Any subsequent MMR occurred in 26/29 (89.7%), 11/12 (91.7%), and 8/16 (50.0%; p=0.006), and MMR at last observation was observed in 23/29 (79.3%), 10/12 (83.3%), and 7/16 (43.8%; p=0.033). The proportions achieving MMR on a different TKI were 3/26 (11.5%), 4/11 (36.4%), and 4/8 (50.0%) across the >0.1-1%, >1-10%, and >10% groups, respectively. Median first-MMR milestones were Months 21, 36, and 42, respectively (log-rank p=0.0003). Each 1-log higher 12-month BCR::ABL1 was associated with lower odds of MMR by Month 24 (odds ratio [OR], 0.13; 95% confidence interval [CI], 0.04-0.41; p=0.0004); results were similar after excluding six patients with prior MMR loss.

Through Month 60, MR4 was documented in 57/63 (90.5%), 19/29 (65.5%), 7/12 (58.3%), and 6/16 (37.5%), and MR4.5 in 52/63 (82.5%), 15/29 (51.7%), 5/12 (41.7%), and 4/16 (25.0%) across the four Month-12 groups, respectively (both p<0.001). Kaplan-Meier median first time to MR4 were Months 18, 36, 54, and 54; for MR4.5, Months 21 and 54 in the first two groups and not reached in the >1-10% and >10% groups.

Among all 57 patients without MMR at Month 12, 41 continued the same TKI, 7 underwent dose escalation, and 9 switched TKIs. Any subsequent MMR occurred in 32/41 (78.0%), 6/7 (85.7%), and 7/9 (77.8%), respectively (exact p=1.00); median Month-12 BCR::ABL1 was 0.722%, 1.231%, and 15.0%, respectively. Among 114 patients with complete dose data, mean relative prescribed dose was 0.875 with versus 0.829 without MMR (difference, 0.046; 95% CI, -0.033 to 0.125; p=0.250); adjusted OR per 0.10 increase was 1.10 (95% CI, 0.83-1.45; p=0.520). Pre-Month-12 relative prescribed dose was not associated with MR4 (adjusted OR per 0.10 increase, 0.82; 95% CI, 0.54-1.22; p=0.323) or MR4.5 (adjusted OR, 1.05; 95% CI, 0.77-1.43; p=0.765) by Month 60.

Conclusions: Higher 12-month molecular burden was associated with a lower likelihood and later achievement of MMR, MR4, and MR4.5. These findings reinforce the prognostic importance of response depth at Month 12 and suggest that, among patients not in MMR, residual molecular burden may help characterize subsequent response trajectories and the likelihood of deep molecular response relevant to future treatment-free remission consideration. Relative prescribed dose was not associated with 12-month MMR or later deep response. Missing 12-month data were concentrated in earlier treatment eras due to incomplete records, introducing potential selection bias and potentially enriching the cohort for recent diagnoses and newer TKIs.

Rikki Williams, MD: No relevant conflicts of interest to declare.